Opinion

Video

Anticipating Key Studies and Pipeline Treatments in mCRC Landscape

Author(s):

Aparna R. Parikh, MD,Marwan G. Fakih, MD

The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.

Related Videos
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Andrew Kuykendall, MD
Prithviraj Bose, MD, and Chandler Park, MD, FACP
Peter Forsyth, MD
Richard Kim, MD, Moffitt Cancer Center
Related Content
FDA
December 20th 2024

FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer

Alex F. Herrera, MD, chief, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, associate medical director, Briskin Center for Clinical Research, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
December 13th 2024

Explore Findings With Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin Lymphoma: With Alex F. Herrera, MD

Maurie Markman, MD, president, Medicine & Science, City of Hope Atlanta, Chicago, and Phoenix
December 10th 2024

The Ongoing Debate: Progression-Free vs Overall Survival as the Primary Study Outcome in Therapeutic Cancer Trials

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Nicole Lamanna, MD, associate clinical professor, medicine, Hematologic Malignancies Section, Hematology/Oncology Division, Columbia University Herberg Irving Comprehensive Cancer Center
November 25th 2024

Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD

Cathy Eng, MD, FACP, FASCO
December 6th 2024

NGS and ctDNA Testing Guide Treatment Selection and Sequencing in mCRC

November Recap
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024